Category: Expert Interview
-
Smarter Trials: Inside Vivalink’s integrated RPM revolution
Vivalink’s Mariel Fabro talks about how integrated remote patient monitoring (RPM) is reshaping decentralized clinical trials.
-
AI in MedTech: Risks, wins, and the road ahead
AI adoption in MedTech lags, but Propel’s Chuck Serrin notes how collaboration and data are unlocking new potential.
-
From risk to readiness: Navigating IRT inspections in clinical trials
As regulators intensify IRT oversight, IQVIA’s Justine Koor outlines how sponsors can prepare and adapt in today’s complex trial landscape.
-
AI in MedTech: Transforming complaint monitoring
IQVIA’s Mike King on how AI enhances complaint handling, product design, and patient safety.
-
The future of AI in healthcare: Why data quality matters
Dr. Mitesh Rao of OMNY Health explains why high-quality, representative data is the key to AI’s success in healthcare.
-
Inside Immunai’s grand collaboration: Mapping the future of immunology
Immunai CEO Noam Solomon discusses the Grand Collaboration Initiative and the future of immune profiling.
-
AI in Pharma: Why regulatory rigor is a catalyst, not a constraint
Ostro CEO Chase Feiger explains how embracing regulation can accelerate AI innovation in life sciences.
-
Balancing the hype and usefulness of AI healthcare
Markus Rothmaier, Head of R&D at Polaroid Therapeutics, talks about how to look beyond the hype to explore more use cases of AI.
Latest posts
-
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
-
Urologic Health secures $11 million for non-invasive bladder monitoring
Urologic Health raises $11million seed funding to advance a catheter-free bladder monitoring platform toward FDA clearance and US market entry.
-
Novo Nordisk’s denecimig cuts bleeding in hemophilia A regardless of inhibitors
Phase III trial shows once‑monthly and once‑weekly denecimig (Mim8) significantly reduces annualized bleeding rate versus standard care, with up to 95% of patients bleed‑free.
-
Beyond the Snapshot: Continuous physiologic monitoring in clinical trials
Vivalink’s CEO discusses how continuous physiologic monitoring is transitioning from a niche tool for early-stage feasibility studies to a core component of late-stage drug development.